Terfenadine

Evidence Level: L5

Predicted Indications: 2

Terfenadine

Pharmacist Assessment Report

Terfenadine: Nasal cavity disease

One-Sentence Summary

Terfenadine is a selective H1-receptor antagonist (antihistamine), originally used for allergic rhinitis, conjunctivitis and idiopathic urticaria. Because this prediction largely overlaps with its existing indications and the drug has well-known cardiac safety problems, the practical repurposing value is low.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Nasal cavity disease
TxGNN Prediction Score	0.9960
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (8 of 8) – CDSCO approval status is not included in this data
Number of Listed Products	8 (valid: 8)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, terfenadine is a selective peripheral H1-receptor antagonist. It blocks histamine from binding to its receptors, which reduces symptoms in histamine-driven allergic conditions.

Allergic urticaria is histamine-mediated, and terfenadine is already used for the closely related idiopathic urticaria. The mechanistic link is therefore highly plausible.

However, the high TxGNN score largely reflects overlap with the existing indication rather than a genuinely new opportunity. Terfenadine was withdrawn from many markets because of QT prolongation and torsades de pointes. Fexofenadine, its active metabolite, is a safer alternative, so there is little rationale to pursue terfenadine itself.

Other predictions follow the same pattern:

Predicted Indication	Score	Evidence Level	Comment
Nasal cavity disease	0.9960	L5	Restates the approved rhinitis use; only indirect and preclinical literature
Rosacea conjunctivitis	0.9933	L5	Prediction only; histamine is not the main driver of the disease

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The most relevant publications for allergic urticaria are listed below. All are reviews; none reports terfenadine-specific trial data for this indication.

PMID	Year	Type	Journal	Key Findings
1972050	1990	Review	Drugs	Updated review of terfenadine: 60 mg twice daily effectively relieves symptoms of allergic rhinitis and allergic skin conditions, particularly chronic urticaria
25097491	2014	Review	Postepy Dermatol Alergol	Cardiovascular safety of antihistamines; terfenadine and astemizole were withdrawn because of QT prolongation
9506246	1998	Review	Drugs	Fexofenadine (active metabolite of terfenadine) did not prolong QTc at doses up to 480 mg/day
9951950	1999	Review	Drugs	Comparative review of second-generation antihistamines, including terfenadine
7530629	1994	Review	Drugs	Urticaria causes and treatment; non-sedating antihistamines are the mainstay for chronic idiopathic urticaria
1715267	1991	Review	Drugs	Acrivastine was similar in efficacy to terfenadine in seasonal allergic rhinitis
1683523	1991	Review	Ann Allergy	Comparative efficacy of second-generation H1 antihistamines, including terfenadine
1979802	1990	Review	J Allergy Clin Immunol	Terfenadine, astemizole, loratadine and cetirizine are first-line options for allergic rhinoconjunctivitis and chronic urticaria
8630719	1996	Comparative study	Ann Allergy Asthma Immunol	Cetirizine and terfenadine versus placebo in seasonal allergic rhinitis
8103973	1993	Review	Ann Allergy	Evolution of H1-antagonist treatment; second-generation agents are less sedating

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
224163	Trexyl 30mg Suspension	Bottle of 60 ml suspension	Not specified
227829	Tedin 120mg Tablet	Strip of 10 tablets	Not specified
224458	Tefdin 60mg Tablet	Strip of 10 tablets	Not specified
223058	Tedin 30mg Syrup	Bottle of 60 ml syrup	Not specified
222731	Tofrin 60mg Tablet	Strip of 10 tablets	Not specified

Eight valid single-ingredient registrations exist in total (the table shows the first five). Manufacturers include Sun Pharmaceutical, Gufic Bioscience, Torrent, Cipla and Psycormedies.

Safety Considerations

Contraindications (from knowledge-graph drug-disease associations, not label text): hypertension, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, coronary artery disease and atherosclerosis, angle-closure glaucoma, and hyperthyroidism (Graves disease, thyrotoxicosis).
Cardiac risk: The published literature reports that terfenadine was withdrawn from many markets because of QT prolongation and torsades de pointes, which depends on CYP3A4 metabolism.
Drug Interactions: 292 interactions are recorded. Major-level examples include:
- Aprepitant
- Cimetidine
- Clarithromycin
- Dolasetron
- Miconazole
- Picosulfuric acid
- Sodium sulfate
- Polyethylene glycol (3350 with electrolytes)
Moderate-level examples include famotidine, loperamide, ondansetron and levofloxacin.

Please also refer to the package insert for label warnings, as these were not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is mechanistically plausible but largely duplicates existing indications, and no terfenadine-specific trials support it. Cardiac risk (QT prolongation) and extensive CYP3A4 interactions, together with the availability of safer alternatives such as fexofenadine, argue against further development.

To proceed, the following is needed:

Package insert warnings and contraindications from the Indian regulatory sources
Detailed mechanism of action data
Terfenadine-specific clinical evidence in urticaria, with a head-to-head comparison against fexofenadine or other second-generation antihistamines
A cardiac safety assessment (QT monitoring and CYP3A4 interaction management plan)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.